Online inquiry

IVTScrip™ mRNA-Anti-ITGAV&ITGB3, MEDI-522(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11302MR)

This product GTTS-WQ11302MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets ITGAV&ITGB3 gene. The antibody can be applied in Sarcoma research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001144999.3; NM_000212.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3685; 3690
UniProt ID P06756; P05106
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ITGAV&ITGB3, MEDI-522(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ11302MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3342MR IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AT-001
GTTS-WQ8116MR IVTScrip™ mRNA-Anti-TNFRSF10B, HGS-ETR2(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA HGS-ETR2
GTTS-WQ14740MR IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA SGN-19A
GTTS-WQ11361MR IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MEDI-551
GTTS-WQ7552MR IVTScrip™ mRNA-Anti-GPC3, GC33(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GC33
GTTS-WQ4185MR IVTScrip™ mRNA-Anti-LAG3, BI-754111(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BI-754111
GTTS-WQ12967MR IVTScrip™ mRNA-Anti-TNFRSF12A, PDL 192(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PDL 192
GTTS-WQ15238MR IVTScrip™ mRNA-Anti-CD38, TAK-079(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA TAK-079
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW